Kiniksa Pharmaceuticals (KNSA) AI Stock Analysis

• Market Cap: $2.74B
• Dividend Yield: N/A
• Average Volume (3M): 528.54K
• Price to Earnings (P/E): 902.7
• Beta (1Y): 0.69
• Revenue Growth: 56.18%
• EPS Growth: N/A
• Country: US
• Employees: 315
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): 0.23
• Shares Outstanding: 43,472,927
• 10 Day Avg. Volume: 437,413
• 30 Day Avg. Volume: 528,542
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.68
• Enterprise Value/Revenue: 3.51
• Enterprise Value/Gross Profit: 4.54
• Enterprise Value/Ebitda: 330.78
• 1Y Price Target: $48.20
• Price Target Upside: 29.92% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 71 Outperform
• Price Target: $33.00 ▼(-11.05% Downside)

Kiniksa Pharmaceuticals demonstrates strong financial performance and positive earnings call sentiment, driven by significant revenue growth and strategic pipeline advancements. However, the high P/E ratio suggests potential overvaluation, and competitive pressures pose risks. The technical analysis supports a bullish outlook, while corporate events reinforce strategic focus and financial stability.

Positive Factors

Revenue Growth

Strong revenue growth from ARCALYST indicates successful market penetration and product adoption, supporting long-term financial stability.

Pipeline Development

Advancing clinical trials for KPL-387 enhances Kiniksa's product pipeline, potentially expanding treatment options and future revenue streams.

Cash Flow Strength

Strong cash flow growth supports operational flexibility and future investments, reinforcing the company's financial health and growth potential.

Negative Factors

Competitive Pressures

Increasing competition could impact market share and pricing power, challenging Kiniksa's ability to maintain its growth trajectory.

Patient Retention Uncertainty

Uncertainty in patient retention and therapy duration could affect long-term revenue stability and necessitate strategic adjustments.

Operating Margin Concerns

Low operating margins suggest inefficiencies that could hinder profitability and require cost management improvements to sustain growth.

Kiniksa Pharmaceuticals Business Overview & Revenue Model

Company Description

Kiniksa Pharmaceuticals is a biopharmaceutical company focused on discovering and developing innovative therapies for patients with debilitating diseases. The company operates primarily in the pharmaceutical sector, specializing in the development of treatments for autoimmune diseases, inflammatory conditions, and pain management. Kiniksa's core products include its lead product, etokimab, which targets key pathways in inflammatory diseases, along with other candidates in its pipeline aimed at providing therapeutic solutions across various conditions.

How the Company Makes Money

Kiniksa Pharmaceuticals generates revenue primarily through the commercialization of its pharmaceutical products, particularly those that receive regulatory approval and enter the market. The company may also pursue partnerships and collaborations with larger pharmaceutical firms for joint development and marketing efforts, which can provide upfront payments, milestone payments, and royalties on sales. Additionally, Kiniksa may receive funding through grants or research contracts, especially for exploratory studies or clinical trials. The success of its revenue model hinges on successfully bringing its products to market and ensuring they meet the needs of healthcare providers and patients.

Kiniksa Pharmaceuticals Financial Statement Overview

Summary

Kiniksa Pharmaceuticals has shown strong financial performance with impressive revenue growth and improving profitability. While the company is still operating at a net loss, the financial trajectory is positive, supported by a strong cash flow and a stable balance sheet with low debt levels.

Income Statement

Kiniksa Pharmaceuticals has shown impressive revenue growth, with significant increases over the past few years, including a 13.7% growth from 2024 to 2025 TTM. Gross profit margin is strong at approximately 93.8% in the TTM period. However, the company is still operating at a net loss, though it has improved significantly from previous years, reducing the net loss from $43.19 million in 2024 to $2.9 million in the TTM period. This indicates a positive trajectory towards profitability.

Balance Sheet

The balance sheet shows a healthy equity position with stockholders' equity growing to $457.49 million. The debt-to-equity ratio is low at approximately 0.02, indicating low leverage and reduced financial risk. However, the company's equity ratio of 76.3% highlights stability, but the historical negative equity in 2021 and prior years is a concern, pointing to past financial instability.

Cash Flow

Cash flow analysis reveals positive trends with free cash flow growing by 72% from 2024 to the TTM period. The operating cash flow to net income ratio is exceptionally strong, indicating efficient cash management. Free cash flow to net income ratio also reflects a robust cash-generating ability. These metrics suggest strong operational efficiency and cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	529.33M	423.24M	270.26M	220.18M	38.54M	0.00
Gross Profit	409.45M	362.33M	213.74M	173.21M	29.44M	-3.81M
EBITDA	5.62M	-45.62M	-22.86M	9.77M	-154.28M	-152.42M
Net Income	4.79M	-43.19M	14.08M	183.36M	-157.92M	-161.38M
Balance Sheet
Total Assets	661.15M	580.55M	526.32M	459.67M	232.80M	349.46M
Cash, Cash Equivalents and Short-Term Investments	307.78M	243.63M	206.37M	190.61M	182.20M	323.48M
Total Debt	9.77M	9.86M	12.26M	5.92M	6.05M	6.99M
Total Liabilities	166.14M	142.12M	87.48M	63.52M	47.76M	37.53M
Stockholders Equity	495.01M	438.44M	438.84M	-492.03M	-675.40M	-517.47M
Cash Flow
Free Cash Flow	66.49M	25.41M	13.17M	5.70M	-146.71M	-136.81M
Operating Cash Flow	66.95M	25.69M	13.30M	5.81M	-126.30M	-136.53M
Investing Cash Flow	3.52M	37.67M	-29.56M	-8.08M	128.63M	-23.44M
Financing Cash Flow	22.30M	12.27M	1.50M	2.52M	5.88M	227.09M

Kiniksa Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 37.10
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KNSA, the sentiment is Positive. The current price of 37.1 is above the 20-day moving average (MA) of 34.64, above the 50-day MA of 31.75, and above the 200-day MA of 24.99, indicating a bullish trend. The MACD of 1.43 indicates Negative momentum. The RSI at 73.54 is Negative, neither overbought nor oversold. The STOCH value of 87.45 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KNSA.

Kiniksa Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HRMY	75 Outperform	$1.92B	10.77	27.58%	―	17.74%	59.96%
KNSA	71 Outperform	$2.74B	902.68	1.03%	―	56.18%	―
CGON	65 Neutral	$2.53B	―	-20.95%	―	―	―
Sector *	51 Neutral	$8.02B	-0.31	-43.38%	2.24%	22.31%	-2.14%
BEAM	50 Neutral	$2.18B	―	-41.94%	―	-82.90%	-155.64%
IRON	43 Neutral	$2.10B	―	-26.36%	―	―	-22.19%
CNTA	33 Underperform	$3.04B	―	-72.95%	―	117.83%	-14.45%

Kiniksa Pharmaceuticals Corporate Events

Kiniksa Pharmaceuticals Highlights Cardiovascular Focus and Growth

On September 3, 2025, Kiniksa Pharmaceuticals released an investor presentation detailing its strategic focus on cardiovascular therapies and its financial health. The company reported strong cash reserves and projected continued revenue growth, particularly from its ARCALYST product, which has generated over $1 billion in revenue since its launch. Kiniksa is also advancing clinical trials for KPL-387 in recurrent pericarditis and maintaining a strong financial position to support ongoing and future developments.

Kiniksa Pharmaceuticals Unveils Phase 2/3 Trial Plans

On June 5, 2025, Kiniksa Pharmaceuticals announced the design and timeline for its Phase 2/3 clinical trial of KPL-387, a monoclonal antibody for treating recurrent pericarditis. The trial is set to begin in mid-2025, with Phase 2 data expected in the second half of 2026. This trial aims to evaluate the efficacy and safety of KPL-387, which is administered subcutaneously, and could potentially expand treatment options for patients with recurrent pericarditis. The announcement underscores Kiniksa’s commitment to advancing its therapeutic options and strengthening its position in the cardiovascular treatment market.

Kiniksa Pharmaceuticals Annual Shareholders Meeting Decisions

On June 3, 2025, Kiniksa Pharmaceuticals held its Annual Meeting of Shareholders where several proposals were voted on and passed. Key decisions included the re-election of directors across three classes, the appointment and remuneration of auditors, and the approval of various financial and governance measures. These resolutions are likely to impact the company’s governance structure and financial operations, potentially influencing its strategic direction and stakeholder relationships.